New inflammatory markers in early rheumatoid arthritis.
2018
Background
Rheumatoid arthritis (RA) is the most common chronic inflammatory disorder and is associated with progressive destruction of synovial joints and physical disability. Therapies with known benefits include disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, as well as more recent biologic agents, such as tumor necrosis factor inhibitors (anti-TNF therapy).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
17
References
22
Citations
NaN
KQI